View in EDS HTML Full Text PDF Full Text

Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.

Saved in:
Bibliographic Details
Title: Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
Authors: Wainberg ZA; Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles Medical Center, David Geffen School of Medicine, 2825 Santa Monica Blvd., Suite 200, Santa Monica, Los Angeles, CA, 90404-2429, USA. ZWainberg@mednet.ucla.edu., Kang YK; Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea., Lee KW; Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea., Qin S; Nanjing Tianyinshan Hospital, The 1st Affiliated Hospital of China Pharmaceutical University, Nanjing, China., Yamaguchi K; Gastroenterological Chemotherapy Department, The Cancer Institute Hospital of JFCR, Tokyo, Japan., Kim IH; Department of Oncology, The Catholic University of Korea, Seoul St Mary's Hospital, Seoul, South Korea., Saeed A; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA., Oh SC; Department of Internal Medicine, Korea University Guro Hospital, Seoul, South Korea., Li J; Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China., Turk HM; Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey., Teixeira A; Gastroenterology Division, Hospital da Senhora da Oliveira, Guimarães, Portugal., Hitre E; Department of Medical Oncology and Clinical Pharmacology 'B', National Institute of Oncology, Budapest, Hungary., Udrea AA; Medical Oncology, Medisprof Cancer Center, Cluj-Napoca, Romania., Cardellino GG; Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy., Sanchez RG; Department of Medical Oncology, Catalan Institute of Oncology, Girona, Spain., Zahlten-Kümeli A; Amgen Inc, Thousand Oaks, CA, USA., Taylor K; Amgen Inc, Uxbridge, UK., Enzinger PC; Department of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.
Source: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association [Gastric Cancer] 2024 May; Vol. 27 (3), pp. 558-570. Date of Electronic Publication: 2024 Feb 03.
Publication Type: Clinical Trial, Phase II; Randomized Controlled Trial; Journal Article
Journal Info: Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 100886238 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1436-3305 (Electronic) Linking ISSN: 14363291 NLM ISO Abbreviation: Gastric Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38308771
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Wainberg+ZA%22">Wainberg ZA</searchLink>; Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles Medical Center, David Geffen School of Medicine, 2825 Santa Monica Blvd., Suite 200, Santa Monica, Los Angeles, CA, 90404-2429, USA. ZWainberg@mednet.ucla.edu.<br /><searchLink fieldCode="AU" term="%22Kang+YK%22">Kang YK</searchLink>; Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Lee+KW%22">Lee KW</searchLink>; Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.<br /><searchLink fieldCode="AU" term="%22Qin+S%22">Qin S</searchLink>; Nanjing Tianyinshan Hospital, The 1st Affiliated Hospital of China Pharmaceutical University, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Yamaguchi+K%22">Yamaguchi K</searchLink>; Gastroenterological Chemotherapy Department, The Cancer Institute Hospital of JFCR, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Kim+IH%22">Kim IH</searchLink>; Department of Oncology, The Catholic University of Korea, Seoul St Mary's Hospital, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Saeed+A%22">Saeed A</searchLink>; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.<br /><searchLink fieldCode="AU" term="%22Oh+SC%22">Oh SC</searchLink>; Department of Internal Medicine, Korea University Guro Hospital, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Li+J%22">Li J</searchLink>; Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Turk+HM%22">Turk HM</searchLink>; Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey.<br /><searchLink fieldCode="AU" term="%22Teixeira+A%22">Teixeira A</searchLink>; Gastroenterology Division, Hospital da Senhora da Oliveira, Guimarães, Portugal.<br /><searchLink fieldCode="AU" term="%22Hitre+E%22">Hitre E</searchLink>; Department of Medical Oncology and Clinical Pharmacology 'B', National Institute of Oncology, Budapest, Hungary.<br /><searchLink fieldCode="AU" term="%22Udrea+AA%22">Udrea AA</searchLink>; Medical Oncology, Medisprof Cancer Center, Cluj-Napoca, Romania.<br /><searchLink fieldCode="AU" term="%22Cardellino+GG%22">Cardellino GG</searchLink>; Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.<br /><searchLink fieldCode="AU" term="%22Sanchez+RG%22">Sanchez RG</searchLink>; Department of Medical Oncology, Catalan Institute of Oncology, Girona, Spain.<br /><searchLink fieldCode="AU" term="%22Zahlten-Kümeli+A%22">Zahlten-Kümeli A</searchLink>; Amgen Inc, Thousand Oaks, CA, USA.<br /><searchLink fieldCode="AU" term="%22Taylor+K%22">Taylor K</searchLink>; Amgen Inc, Uxbridge, UK.<br /><searchLink fieldCode="AU" term="%22Enzinger+PC%22">Enzinger PC</searchLink>; Department of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100886238%22">Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association</searchLink> [Gastric Cancer] 2024 May; Vol. 27 (3), pp. 558-570. <i>Date of Electronic Publication: </i>2024 Feb 03.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Randomized Controlled Trial; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer-Verlag+Tokyo%22">Springer-Verlag Tokyo </searchLink><i>Country of Publication: </i>Japan <i>NLM ID: </i>100886238 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1436-3305 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214363291%22">14363291 </searchLink><i>NLM ISO Abbreviation: </i>Gastric Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38308771
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10120-024-01466-w
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 558
    Titles:
      – TitleFull: Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wainberg ZA
      – PersonEntity:
          Name:
            NameFull: Kang YK
      – PersonEntity:
          Name:
            NameFull: Lee KW
      – PersonEntity:
          Name:
            NameFull: Qin S
      – PersonEntity:
          Name:
            NameFull: Yamaguchi K
      – PersonEntity:
          Name:
            NameFull: Kim IH
      – PersonEntity:
          Name:
            NameFull: Saeed A
      – PersonEntity:
          Name:
            NameFull: Oh SC
      – PersonEntity:
          Name:
            NameFull: Li J
      – PersonEntity:
          Name:
            NameFull: Turk HM
      – PersonEntity:
          Name:
            NameFull: Teixeira A
      – PersonEntity:
          Name:
            NameFull: Hitre E
      – PersonEntity:
          Name:
            NameFull: Udrea AA
      – PersonEntity:
          Name:
            NameFull: Cardellino GG
      – PersonEntity:
          Name:
            NameFull: Sanchez RG
      – PersonEntity:
          Name:
            NameFull: Zahlten-Kümeli A
      – PersonEntity:
          Name:
            NameFull: Taylor K
      – PersonEntity:
          Name:
            NameFull: Enzinger PC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2024 May
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1436-3305
          Numbering:
            – Type: volume
              Value: 27
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
              Type: main
ResultId 1